Villanova Investment Management Co LLC Has $1.54 Million Stock Holdings in InMode Ltd. (NASDAQ:INMD)

Villanova Investment Management Co LLC grew its stake in shares of InMode Ltd. (NASDAQ:INMD) by 10.8% in the fourth quarter, according to the company in its most recent filing with the SEC. The firm owned 91,956 shares of the healthcare company’s stock after acquiring an additional 8,972 shares during the quarter. Villanova Investment Management Co LLC owned about 0.13% of InMode worth $1,536,000 as of its most recent SEC filing.

Several other large investors also recently modified their holdings of INMD. River Road Asset Management LLC bought a new stake in InMode during the fourth quarter worth about $8,572,000. Norges Bank bought a new stake in shares of InMode during the 4th quarter worth approximately $2,943,000. Seizert Capital Partners LLC boosted its position in shares of InMode by 105.2% during the 4th quarter. Seizert Capital Partners LLC now owns 250,627 shares of the healthcare company’s stock worth $4,185,000 after acquiring an additional 128,483 shares in the last quarter. Systematic Financial Management LP increased its stake in InMode by 13.3% in the third quarter. Systematic Financial Management LP now owns 982,111 shares of the healthcare company’s stock valued at $16,647,000 after acquiring an additional 115,492 shares during the last quarter. Finally, Barclays PLC raised its position in InMode by 113.5% during the third quarter. Barclays PLC now owns 169,630 shares of the healthcare company’s stock valued at $2,876,000 after purchasing an additional 90,173 shares in the last quarter. 68.04% of the stock is owned by institutional investors and hedge funds.

InMode Stock Performance

Shares of INMD opened at $17.74 on Tuesday. InMode Ltd. has a 52 week low of $14.87 and a 52 week high of $21.76. The stock has a market capitalization of $1.23 billion, a price-to-earnings ratio of 7.55 and a beta of 2.08. The stock has a fifty day moving average of $18.34 and a 200-day moving average of $17.79.

Analyst Ratings Changes

A number of equities research analysts have weighed in on the company. Needham & Company LLC reaffirmed a “hold” rating on shares of InMode in a report on Tuesday, February 4th. Barclays raised their price objective on InMode from $26.00 to $29.00 and gave the company an “overweight” rating in a research note on Wednesday, February 5th. Three research analysts have rated the stock with a hold rating and two have given a buy rating to the company’s stock. According to MarketBeat.com, the stock has a consensus rating of “Hold” and an average price target of $22.25.

InMode Company Profile

InMode Ltd. designs, develops, manufactures, and markets minimally invasive aesthetic medical products based on its proprietary radiofrequency assisted lipolysis and deep subdermal fractional radiofrequency technologies in the United States and internationally. The company offers minimally invasive aesthetic medical products for various procedures, such as liposuction with simultaneous skin tightening, body and face contouring, and ablative skin rejuvenation treatments, as well as for use in women's health conditions and procedures.